Physician profile
Ned Weiss
NPI 1093736522
$6,373.84
in general payments reported to CMS, 2019-2025
48 companies · $806 in 2025
The $806 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,198 · 2020: $713 · 2021: $797 · 2022: $861 · 2023: $1,287 · 2024: $710 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,761 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,761.14 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $767.67 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Dexcom, INC. | $529.52 | 2019-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $511.53 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $384.74 | 2019-2022 | |
| Abbvie INC. | $340.41 | 2019-2025 | Synthroid |
| Mannkind Corporation | $338.21 | 2019-2025 | Afrezza |
| Novo Nordisk INC | $332.90 | 2019-2024 | Rybelsus, Ozempic |
| Amgen INC. | $238.36 | 2019-2025 | Tepezza, Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $232.87 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.34 | 2019-2025 | Jardiance, Synjardy |
| Medtronic, INC. | $221.13 | 2021-2025 | Minimed 780g |
| Abbott Laboratories | $220.26 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $197.67 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $178.22 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $155.32 | 2019-2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $149.90 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $104.74 | 2023 | |
| Companion Medical, INC. | $103.81 | 2019-2020 | |
| Insulet Corporation | $99.06 | 2019-2023 | Omnipod |
| Medtronic Minimed, INC. | $81.57 | 2019-2020 | |
| Intuity Medical INC | $74.21 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Ascendis Pharma Endocrinology INC | $73.19 | 2023-2025 | Yorvipath |
| Radius Health, INC. | $68.99 | 2019-2024 | Tymlos |
| Becton, Dickinson and Company | $59.09 | 2019-2022 | |
| Ascensia Diabetes Care US INC. | $58.65 | 2022-2024 | |
| Tandem Diabetes Care, INC. | $56.65 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $52.07 | 2024-2025 | Unithroid |
| Esperion Therapeutics, INC. | $48.30 | 2023-2024 | Nexletol |
| Amphastar Pharmaceuticals, INC. | $35.86 | 2023-2024 | Baqsimi |
| Ipsen Biopharmaceuticals, INC | $35.15 | 2022-2023 | Somatuline Depot |
| Horizon Therapeutics Plc | $33.91 | 2022-2023 | Tepezza |
| Kyowa Kirin, INC. | $33.15 | 2024 | Crysvita |
| Ibsa Pharma INC. | $30.93 | 2020 | |
| Senseonics, Incorporated | $28.00 | 2019 | |
| Sequel Med Tech, LLC | $25.82 | 2025 | Twiist |
| Corcept Therapeutics | $24.78 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $22.71 | 2022 | |
| Bigfoot Biomedical INC | $21.60 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.45 | 2024 | Cycloset |
| Pfizer INC. | $18.92 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.78 | 2019 | |
| Madrigal Pharmaceuticals | $18.01 | 2025 | Rezdiffra |
| Tolmar, INC. | $17.94 | 2023 | |
| Intra-Sana Laboratories | $17.48 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Cequr Corporation | $16.50 | 2024 | Cequr Simplicity |
| Shire North American Group INC | $15.86 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $14.66 | 2025 | Imcivree |
| Antares Pharma, INC. | $13.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ned Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.